Insurers weigh the short-term cost of GLP-1 therapies (up to ~$17K annually) against the long-term savings from reduced obesity-related complications
It is very plausible that these patients that have poor blood glucose regulation have faults in their upper digestive tract and those bitter receptors and the sweet receptors that are regulating the production of the GIP and the GLP-1 may not be doing their thing properly or the L cells may be receiving the signal but are not healthy enough to produce enough GLP-1
Despite some data showing differing bioavailability by injection site, the FDA highlights that the maximal subcutaneous bioavailability of semaglutide is 89%
This synergy, combined with powerful GLP-1 appetite suppression, creates the most potent weight loss effect seen in any clinical trial to date
The full Certificate of Analysis is published in our COA database before any vial ships
To manage nausea, stick to small, bland meals think plain wheat toast, crackers, oatmeal, or rice